LIFNano Therapeutics - about the company

LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF).

Following the Founder's discovery that LIF is of profound importance in immune self-tolerance in addition to the known key role of LIF in stem cells and tissue maintenance, the therapeutic potential of LIF has been harnessed by invention of a targeted delivery platform using nanotechnology in collaboration with Yale University. After extensive proof of concept that our nano-formulated LIF is safe and efficacious, LIFNano Therapeutics is now taking LIF to patients.

Management team

Florian Kemmerich MSc (Chairman of Board of Directors)

Florian is Managing Partner at Bamboo Capital, Founder of Ryan-Kay, Advisor of several investment funds and Board Member of numerous organisations. He holds a Bachelor of Business Administration, Master of Science and different diploma on executive and personal development. As a corporate advisor and CEO mentor he leverages his extensive background on start-ups in biotech, medical device and life science to help building and positioning organisations in the competitive global marketplace.
Passionate about translational science, disruptive technologies, fundraising and global life sciences. Prized for building a major international business leader network for small and medium enterprises in healthcare and life sciences. Valued for successful problem solving by primarily crafting the vision, assessing unmet market needs, designing directed strategies and attracting the required (human) capital. Comfortable, proficient and valuable in global intercultural management with a deep understanding of the industry along with a solid knowledge of market dynamics and cultures.
With over 25 years in life sciences Florian held C-level positions at B. Braun Medical, Olympus Biotech, Small Bone Innovations (now Stryker) and lead several early & commercial stage startups. Fluent in German, English, Spanish, French, Italian.

Olivier Jarry MSc, MEng, MBA (Chief Executive Officer)

Partner at Ryan-Kay. Partner/Advisor of several investment funds and strategy groups, and Board Member of organizations in healthcare and digital health. Olivier combines expertise in biopharma and biotechnologies over the past 20 years, with business design and management over the last 32 years: strategy, operational planning, organization design, mergers, acquisitions and alliances in the Americas, Europe and former USSR, Middle-East Africa, India, China and Japan. Olivier has worked on strategy and planning for biologics at Bristol-Myers Squibb, synthetic biology and gene therapy at Intrexon, expanding existing businesses and building new businesses as a senior executive at Novartis, Bayer and as a strategy consultant at Pfizer, J&J, Sanofi, GSK. Olivier holds two Masters in Science and an MBA jointly granted by New York University Stern School of Business (NYU), London School of Economics and Political Science (LSE), and Hautes Études Commerciales (HEC) Paris. Fluent in English, French, Italian and has operated in Spanish, Portuguese and German.

Su Metcalfe PhD (Founder, Chief Scientific Officer, Director)

Founder of LIFNano Therapeutics and full time CSO. Su received her PhD in Pathology at the University of Cambridge where she continued as principal investigator, latterly moving to the University's Clinical School researching into immune tolerance. Su's committee work in the Clinical School included introduction of the cross-schools NanoMed Initiative with University's Nanosciences. Visiting Fellowships and close collaborations include Stanford, Harvard, and Yale in addition to links with Astellas, Novartis, and Merck Serono. Research focus throughout has been the molecular biology of immune regulation and its commonalities with regulation of stem cells. Su discovered the role of the stem cell factor LIF in immune tolerance soon followed by a second discovery of the LIF/IL-6 axis in T lymphocyte lineage determination whilst collaborating with Terry Strom at Harvard. Together with Tarek Fahmy of Yale University Su is lead inventor and co-owner of two LIFNano patents shared with Yale. Awards include British Technology Group award for Academic Enterprise; Merck-Serono Grant for Multiple Sclerosis Innovation 2014; shortlisted 2016 Rolex Award for Enterprise.

Andrew Wood (Chief Financial Officer)

1st Class Hons Oxford (Biochemistry). Andrew has extensive finance and commercial experience in startup, early stage and established businesses. He is now building a portfolio of early stage life sciences companies. Previously he was CFO of Oxford Biomedica.

Commercial, Scientific and Clinical Advisors

Magda Papadaki

Head of Manufacturing Innovation: Association of the British Pharmaceutical Industry
SPECIALIZATION: Advanced Therapy and Precision Medicine

Nick Dunscombe

Vice President, Business & Commercial Development, Astellas

Gavin Giovannoni

Professor of Neurology, Barts and the London School of Medicine and Dentistry

Ursula Boschert

Head of NeuroImmunology, EMD Serono Inc.

Professor Tarek Fahmy, Chairman

Yale University: Associate Professor of Biomedical Engineering and Immunobiology

Professor Sir Mark Welland

University of Cambridge: Professor of Nanotechnology and Head of the Nanoscience Centre

Professor Terry B Strom

Harvard University: Professor of Medicine & Surgery

Professor Niels Hellings

Hasselt University, Belgium: Associate Professor Immunology and Vice-Director of Biomed

Cambridge BioMedical Campus Clinical Trials Unit